Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus nonsteroidal aromatase inhibitor vs placebo in postmenopausal HR+, HER2- advanced breast cancer (phase 3)
jRCT2080222697Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib + nonsteroidal aromatase inhibitor with Placebo + nonsteroidal aromatase inhibitor (2 arms). Started Dec 2014; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222697.